
Abbott Laboratories (NYSE:ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.
The company reported third-quarter sales of $11.37 billion, slightly missing the consensus of $11.40 billion.

Abbott Laboratories (NYSE:ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.
The company reported third-quarter sales of $11.37 billion, slightly missing the consensus of $11.40 billion.